Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 13/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27809972 | 0.98 | POLB (0.50) | POLBKMT2APPARDCNR1CNR2 | |
| SCHEMBL8430620 | 0.98 | POLB (0.50) | POLBKMT2APPARDCNR1CNR2 | |
| SCHEMBL28654691 | 0.82 | POLB (0.49) | POLBKMT2APPARDCNR1CNR2 | |
| SCHEMBL12412755 | 0.81 | POLB (0.48) | POLBKMT2APPARDCNR1CNR2 | |
| SCHEMBL1300785 | 0.81 | POLB (0.48) | POLBKMT2APPARDCNR1CNR2 | |
| SCHEMBL3126218 | 0.81 | POLB (0.52) | POLBKMT2APPARDCNR1CNR2 | |
| SCHEMBL2702353 | 0.81 | CA1 (0.55) | POLBKMT2APPARDCNR1CNR2 | |
| SCHEMBL6074694 | 0.80 | POLB (0.43) | POLBKMT2APPARDCNR1CNR2 | |
| SCHEMBL14194277 | 0.79 | POLB (0.47) | POLBKMT2APPARDCNR1CNR2 | |
| SCHEMBL8430618 | 0.79 | POLB (0.47) | POLBKMT2APPARDCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | claimed |
| US-20030171425-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2003-09-11 | — | — | US | claimed |
| US-6528510-B1 | Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | claimed |
| US-6512006-B1 | Novel 3-position Nitrogen substituted 6,6- disubstituted-5, 6-dihydropyrones and related compounds possess antiviral properties | WARNER-LAMBERT COMPANY | 2003-01-28 | — | — | US | claimed |
| US-6423718-B1 | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-23 | — | — | US | claimed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | claimed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-6927217-B2 | HIV protease inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20050075390-A1 | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6855850-B2 | Method of manufacturing fluorine compounds, and a method of recovering or regenerating precursors of fluorinating agents | DAIKIN INDUSTRIES LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-6852711-B2 | Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-6528510-B1 | Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-6512006-B1 | Novel 3-position Nitrogen substituted 6,6- disubstituted-5, 6-dihydropyrones and related compounds possess antiviral properties | WARNER-LAMBERT COMPANY | 2003-01-28 | — | — | US | disclosed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
| EP-0526849-B1 | Substituted N-Fluoropyridiniumsulfonate, intermediates therefor and preparation processes thereof | DAIKIN IND LTD (JP) | 1999-12-01 | — | — | EP | disclosed |
| US-5374732-A | Chemical intermediates as fluorination agents | DAIKIN INDUSTRIES, LTD. (JP) | 1994-12-20 | — | — | US | disclosed |
| EP-0526849-A1 | Novel substituted N-Fluoropyridiniumsulfonate, intermediates therefor and preparation processes thereof | DAIKIN INDUSTRIES, LTD. (JP) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | POLB 2779/4885KMT2A 714/4885PPARD 2559/4885 |
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | POLB 1862/4885KMT2A 2939/4885PPARD 4355/4885 |
| US-20050075390-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | POLB 1760/4885KMT2A 2859/4885PPARD 4318/4885 |
| US-20030171425-A1 | HIV protease inhibitors | DNPEP, PRSS1, PREP | POLB 2048/4885KMT2A 2806/4885PPARD 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.